Lowering Dupilumab Dose in Controlled Eczema
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study looks at whether people with well-controlled eczema can safely lower their dose of dupilumab (an injected medication). It aims to see if a reduced dose still keeps eczema under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with atopic eczema (eczema)
- You are currently receiving dupilumab 300 mg injections every 2 weeks
- Your eczema is well-controlled according to your doctor's Treat-to-Target criteria
- You are willing to possibly have your dupilumab dose lowered
- You are not using any other systemic (whole-body) immunotherapy for eczema or another condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well Dupilumab works over time for people with atopic dermatitis (eczema). It includes adults, teens, and children ages 6 and up.
This study looks at whether children with well-controlled eczema can safely reduce how often they take Dupixent. It aims to find the lowest effective dose to keep eczema under control.
This trial studies why eczema (“atopic dermatitis”) varies in severity even when people receive the medicine dupilumab. It may help doctors better predict who responds well and how to monitor treatment.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
This trial studies how the body’s “molecular signals” change in the skin after using dupilumab for eczema. It may help researchers understand who benefits most from treatment.
This Phase 4 study looks at how dupilumab works in people with moderate-to-severe atopic dermatitis (eczema), and whether the mechanism differs across ethnic backgrounds. If you’re eligible, it may help doctors understand who benefits most from dupilumab.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.